Full Press Release Details
Publishes Detailed Interim Phase 1 Data of its COVID-19 Vaccine Candidate, CVnCoV
Germany/ BOSTON, USA - November 10, 2020 - CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today
announced publication of detailed interim Phase 1 data, following the reporting of positive topline data on November 2, 2020.
The manuscript is available on medRxiv and will also be
submitted for publication in a peer-reviewed journal.
The previously announced
interim data showed that CVnCoV was generally well tolerated across all tested doses (2-12 g) and induced strong binding
and neutralizing antibody responses in addition to first indication of T cell activation. The quality of immune response
was found to be comparable to recovered COVID-19 patients, closely mimicking the immune response after natural COVID-19 infection.
a conference call and webcast today at 5 p.m. CET (11 a.m. EST) to provide more insight on the detailed Phase 1 interim trial
data. The live webcast link and corresponding presentation slides can be accessed via the Investor Relations section of the CureVac
homepage at https://www.curevac.com/en/newsroom/events/
CureVac began development
of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimized, non-chemically modified mRNA, encoding
the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. The Phase 1 clinical study of CVnCoV began in June
2020 at clinical study centers in Germany and Belgium in collaboration with the Coalition for Epidemic Preparedness Innovation
(CEPI). At the end of September 2020, CVnCoV entered a Phase 2a clinical trial in Peru and Panama, extending clinical studies
into older adults and regions with high-incidence of COVID-19 infections. CureVac plans to initiate a pivotal Phase 2b/3 clinical
study by the end of 2020. Clinical trial material is provided by the company's substantial production capacities for mRNA
vaccines at its headquarters in T bingen. The company is currently expanding those manufacturing capacities to allow for
broad-scale manufacturing of CVnCoV for potential commercial supply preparedness.
CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20
years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's
proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its
own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep
clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases.
CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in T bingen, Germany,
and employs approximately 500 people at its sites in T bingen, Frankfurt, and Boston, USA. Further information can be found
CureVac Media Contact
Vice President Communications
T: +49 7071 9883-1577
CureVac Investor Relations
Dr. Sarah Fakih, Vice President
T: +49 7071 9883-1298
M: +49 160 90 496949
Forward-Looking Statements
This press release contains statements that constitute "forward looking statements" as that term is defined in
the United States Private Securities Litigation Reform Act of 1995, including statements that express the opinions, expectations,
beliefs, plans, objectives, assumptions or projections of CureVac (the "company") regarding future events or future
results, in contrast with statements that reflect historical facts. Examples include discussion of the company's strategies,
financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology
such as "anticipate," "intend," "believe," "estimate," "plan," "seek,"
"project," or "expect," "may," "will," "would," "could,"
"potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the company.
However, these forward-looking statements are not a guarantee of the company's performance, and you should not place undue
reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances,
including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability
to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty
of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture
any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors.
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on
such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements included in this press release are made only as of the date
hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information,
please reference the company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC).
You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.